RayzeBio, Inc.
RayzeBio, Inc. (RYZB): 9 pipeline candidates · ~73 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
73.1 months
0% dilution
Lead: Phase 3
9 candidates
N/A
N/A
A transparent, data-derived signal for RayzeBio, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$252.3M
Quarterly Burn
$21.7M
Runway
73.1 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (9 candidates)
| Drug | Phase |
|---|---|
| lanreotide | Phase 3 |
| octreotide | Phase 3 |
| ryz101 | Phase 1/Phase 2 |
| ryz101 dose level -1 | Phase 1 |
| ryz101 dose level 1 | Phase 1 |
| ryz101 dose level 2 | Phase 1 |
| ryz101 dose level 3 | Phase 1 |
| ryz401 | Phase 1 |
| ryz801 | Phase 1/Phase 2 |
Frequently asked questions
How many drug candidates are in RayzeBio, Inc.'s pipeline?
RayzeBio, Inc. (RYZB) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is RayzeBio, Inc.'s lead drug candidate?
RayzeBio, Inc.'s most advanced tracked candidate is lanreotide (Phase 3) for GEP-NET.
What is RayzeBio, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, RayzeBio, Inc. has approximately 73.1 months of cash runway.
Get the full picture on RayzeBio, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.